DENISE CLARIDY: Open Payments
NPI 1386102119 · ATLANTA, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,618 in 124 payments from 18 companies in 2025. Trend: 2023 $567 · 2024 $2,061 · 2025 $3,618
Food & beverage: $3,618
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 19 | $843 |
| AstraZeneca Pharmaceuticals LP | 20 | $714 |
| CSL Behring | 17 | $405 |
| GlaxoSmithKline, LLC. | 14 | $361 |
| Novartis Pharmaceuticals Corporation | 14 | $304 |
| BioCryst US Sales Co., LLC | 9 | $200 |
| Verona Pharma, Inc. | 7 | $160 |
| Amgen Inc. | 6 | $112 |
| Grifols USA, LLC | 3 | $100 |
| Regeneron Healthcare Solutions, Inc. | 3 | $90 |
Products named: DUPIXENT, TEZSPIRE, Hizentra, NUCALA, FASENRA, ORLADEYO, Ohtuvayre, XOLAIR.
Industry payments across GA — which companies pay providers there.
